Solution Empowers Clinical Research Sequencing with Quick Workflow,
Minimal Sample Input
SANTA CLARA, Calif.--(BUSINESS WIRE)--
Agilent Technologies Inc. (NYSE: A) today introduced the SureSelectQXT
Reagent Kit, a revolutionary next-generation sequencing target
enrichment solution that produces sample-to-sequencing-ready libraries
in just seven hours with only 50 ng of input gDNA.
Designed to meet the exacting needs of clinical researchers for a fast,
easy, same-day sample-to-sequencing workflow, SureSelectQXT
kits are three times faster than existing transposase-based methods and
require 30 percent less hands-on time. They are optimized for use with
samples of limited availability and provide superior coverage of genomic
targets for confident variant calling. Combined with the fastest
sequencers on the market, these kits make sample-to-data in 24 to 36
hours a reality.
“We are excited to provide this fast, powerful new target enrichment
solution to the clinical research community,” said Victor Fung, senior
director of global marketing for Agilent’s Diagnostics and Genomics
Division. “With SureSelectQXT Reagent kits, researchers can
quickly analyze exomes or target-specific genes with superior variant
calling accuracy, and go from sample to sequencing in the same day.”
SureSelectQXT kits’ unprecedented speed is achieved by
coupling transposase-based library preparation with major advancements
in hybridization chemistry, significantly decreasing hybridization time
from 16 hours to 90 minutes while maintaining high performance. The
kits’ proven hybridization technology enables the sensitivity and
specificity required for the complete and accurate variant analysis of
exomes or custom genomic regions. The kits are complemented by an
extensive portfolio of target enrichment solutions for library
preparation, capture, automation, quality control and data analysis
portfolio is the industry’s leading target enrichment solution. With
reagents that address needs from every step of the sequencing workflow,
SureSelect enables a complete solution for researchers to quickly and
easily analyze specific regions of the genome, transcriptome and
methylome. As part of the complete solution, SureSelect is supported by
SureDesign software that enables custom capability; Bravo automation
platforms that enable reproducibility and high-throughput sample
processing; and SureCall software that enables quick, easy, streamlined
analysis of genomic regions of interest.
For more information about SureSelectQXT visit: www.agilent.com/genomics/qxt.
About Agilent in Genomics
Agilent Technologies is a global leader in target enrichment solutions
for next-generation sequencing and genomic microarrays. By synthesizing
custom complex mixtures of long oligonucleotides, SureSelect and
HaloPlex target enrichment solutions enable researchers to identify
genomic regions of interest for focused, cost-effective variant
profiling, with workflows that generate sequencing-ready libraries in
just one day. Agilent’s unique manufacturing technology is the
foundation for Agilent’s genomics portfolio which includes SurePrint
technology for accurate genome-wide measurement of gene expression,
arrayCGH for combined copy number assessment with SNP information, and
SureFISH, for highly sensitive and specific oligonucleotide fluorescent
in-situ hybridization. Agilent also offers a microfluidic Bioanalyzer
and TapeStation with complementary reagents and software for sample
quantitation and quality assessment. For more information visit Agilent
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement
company and a technology leader in chemical analysis, life sciences,
diagnostics, electronics and communications. The company’s 20,600
employees serve customers in more than 100 countries. Agilent had
revenues of $6.8 billion in fiscal 2013. Information about Agilent is
available at www.agilent.com.
On Sept. 19, 2013, Agilent announced plans to separate into two publicly
traded companies through a tax-free spinoff of its electronic
measurement business. The new company is named Keysight Technologies,
Inc. The separation is expected to be completed in early November 2014.
NOTE TO EDITORS: Further technology, corporate citizenship and executive
news is available at www.agilent.com/go/news.
Agilent Technologies Inc.
Susan Berg, +1 408-553-7093
Source: Agilent Technologies Inc.